ssussu
☆    

China,
2017-08-29 13:38
(3227 d 18:58 ago)

Posting: # 17748
Views: 3,365
 

 Extended release dosage form BE design [Design Issues]

Dear all,
According to the FDA guidance for Mirabegron extended release tablets, there are 3 studies included. Why the study of 25mg strenth under fed condition dose not need?
Additionally, about a extended release drug,if the half life is very long e.g. 70hr,dose the AUC truncte to AUC0-72h?
Is there guidance for extended release drug specially from FDA?

Please kindly give me some advice. Thank you!
UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
346 visitors (0 registered, 346 guests [including 18 identified bots]).
Forum time: 08:37 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5